New York — A first in-human study using the gene-editing tool Crispr has a company named after the technology and its partner, Vertex Pharmaceuticals, claiming an early victory in treating two inherited blood disorders.

Crispr Therapeutics and Vertex said a pair of patients — one suffering from beta thalassemia and the other with severe sickle cell disease — saw benefits from one-time treatment with CTX001. While they’ve been followed for just nine months and four months, respectively, their painful flare-ups and once-routine need for blood transfusions stopped after getting the therapy. Both developed severe complications including infections that were deemed unrelated to the gene-editing treatment...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now